PEAQX is primarily utilized in neuroscience research as a selective antagonist for the GluK1 kainate receptor subtype. Its application is crucial in studying the role of kainate receptors in synaptic transmission and plasticity. Researchers use PEAQX to block GluK1 receptors, allowing them to investigate the receptor's involvement in neurological disorders such as epilepsy, chronic pain, and neurodegenerative diseases. This compound aids in understanding the mechanisms of excitatory signaling in the brain and contributes to the development of potential therapeutic strategies targeting kainate receptors.